Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Harvard Medical School Curriculum Vitae
Document related concepts
no text concepts found
Transcript
Harvard Medical School Curriculum Vitae Date Prepared: July 1, 2014 Name: Tracy Batchelor Office Address: Stephen E. and Catherine Pappas Center for Neuro-Oncology Yawkey 9E Massachusetts General Hospital 55 Fruit Street Boston, Massachusetts 02114 Home Address: 33 Stoney Brook Road Sherborn, Massachusetts 01770 Work Phone: 617-643-1938 Work E-Mail: [email protected] Work facsimile: 617-643-2591 Place of Birth: Abbeville, Georgia, USA Date of Birth: April 11, 1964 Education: 1986 Bachelor of Science Biology Emory University 1990 Doctor of Medicine Medicine Emory University 1998 Master of Public Health Epidemiology Harvard University 2005 Master of Science Cancer Epidemiology Harvard University 1990-1991 Intern Medicine Yale-New Haven Hospital 1991-1994 Resident Neurology Massachusetts General Hospital 1994-1995 Fellow Neuro-Oncology Memorial SloanKettering Cancer Center 1998-2000 Fellow Cancer Epidemiology Harvard School of Public Health 2004-2006 Graduate Physician Leadership Certificate Program Massachusetts General Hospital Postdoctoral Training: Tracy T. Batchelor 4/29/20171 Physician Organization Faculty Academic Appointments: 1996-1998 Instructor Department of Neurology Harvard Medical School 1999-2005 Assistant Professor Department of Neurology Harvard Medical School 2005-2010 Associate Professor Department of Neurology Harvard Medical School 2010-present Professor Department of Neurology Harvard Medical School 2012-present Giovanni Armenise Harvard Professor Department of Neurology Harvard Medical School Appointments at Hospital/Affiliated Institutions: 1996-2005 Assistant in Neurology Department of Neurology Massachusetts General Hospital 2005-2012 Associate Neurologist Department of Neurology Massachusetts General Hospital 2012-present Neurologist Department of Neurology Massachusetts General Hospital 2006-present Consultant Department of Radiation Oncology Massachusetts General Hospital Major Administrative Leadership Positions: Local 1996-2006 Director, Neuro-Oncology Fellowship Training Program Department of Neurology, Cancer Center Massachusetts General Hospital 1998-present Chief, Division of Neuro-Oncology Department of Neurology, Cancer Center Massachusetts General Hospital 2001-present Executive Director, Stephen E. And Catherine Pappas Center for Neuro-Oncology Cancer Center Massachusetts General Hospital 2008-present Co-Chair, Clinical Trials Committee Neuro-Oncology Program, Dana-Farber/Harvard Cancer Center 2013-present Co-Leader, Brain Cancer Program Dana-Farber/Harvard Cancer Center 1999 Co-Chair, National Tracy T. Batchelor Annual Meeting 4/29/20172 Clinical Neuro-Oncology Scientific Session, Toronto, Canada American Academy of Neurology 2004 Co-Chair, Basic Science Neuro-Oncology Session, San Francisco, California Annual Meeting American Academy of Neurology 2005 Co-Chair, Neuro-Oncology Therapy Session, Miami, Florida Annual Meeting American Academy of Neurology 2009 Co-Chair, Neuro-Oncology Science Session, Seattle, Washington Annual Meeting American Academy of Neurology 2009 Symposium Co-Chair, Gliomas Annual Symposium William Guy Forbeck Foundation 2010 Co-Chair Integrated Neuroscience Session – Neuro-Oncology Annual Meeting American Academy of Neurology 2009-present Member Board of Scientific Advisors National Brain Tumor Society 2010-present Member Medical Advisory Board Voices Against Brain Cancer 2010 Co-Chair Society for Neuro-Oncology Meeting, Montreal, Canada Annual Education Day 2012-2014 Vice-Chair (elected) Section on Neuro-Oncology American Academy of Neurology 2014-2016 Chair (elected) Section on Neuro-Oncology American Academy of Neurology 1989-1990 Student Member, Admissions Committee Emory University School of Medicine 1993-1994 Resident Member, Neurology Residency Education Committee Department of Neurology Massachusetts General Hospital 1993-1994 Resident Member, Department of Neurology Neurology-Psychiatry Task Force Massachusetts General Hospital 1993-1994 Resident Member, Department of Neurology Clinical Neurosciences Committee Massachusetts General Hospital Committee Service: Local Tracy T. Batchelor 4/29/20173 1997-2000 Member, Advisory Board Patient and Family Support Program Cancer Center Massachusetts General Hospital 1996-2001 Member, Clinical Trials Improvement Committee Cancer Center Massachusetts General Hospital 2001-2004 Member, Clinical Trials Audit Committee Cancer Center Massachusetts General Hospital 2001-2008 Member, Neuro-Oncology Clinical Trials Subcommittee Dana-Farber/Harvard Cancer Center 1999-2001 Member, Population Science Committee Dana-Farber/Harvard Cancer Center 2000-2001 Member, Neuro-Oncology SPORE Planning Committee Dana-Farber/Harvard Cancer Center 2000-2002 Voting Member, Scientific Review Committee Dana-Farber/Harvard Cancer Center 2006-present Member, Executive Committee Cancer Center Massachusetts General Hospital 2006-present Member, Chief’s Council Cancer Center Massachusetts General Hospital 2010, 2013 Ad Hoc Committee of Professors Harvard Medical School 2012-present Research Council Department of Neurology Massachusetts General Hospital 2012-present Clinical Leadership Council Department of Neurology Massachusetts General Hospital 1998-2008 Chair, Non-Astrocytoma, NonTherapeutics Committee New Approaches to Brain Tumor Therapy (NABTT) Consortium, National Cancer Institute 2000 Consultant, Orphan Products Development Program U.S. Food and Drug Administration 2004-2005 Member, Brain Disease Site Team American College of Surgeons Commission on Cancer 2006-2010 Member, Preuss Award Committee American Academy of Neurology 2010-present Member, PCNSL Working Group Lymphoma Steering Committee National Cancer Institute 2010 Member, External Review Committee National Tracy T. Batchelor Departments of Neuro-Oncology and and Neurosurgery M. D. Anderson Cancer Center 4/29/20174 International 2002 Co-Chair Workshop on Primary Central Nervous System Lymphoma, 8th International Conference on Malignant Lymphoma, Lugano, Switzerland 2002-present Co-Founder and Co-Chair International Primary Central Nervous System Lymphoma Collaborative Group 2010 Co-Chair Primary CNS Lymphoma Symposium Freiburg, Germany 2013-2014 Scientific Advisory Committee Asian Society for Neuro-Oncology 2014 Annual Meeting Istanbul, Turkey Professional Societies: 1991-1995 Junior Member, American Academy of Neurology 1996-present Member, American Academy of Neurology 1996-present 1996-present Member, Section on Neuro-Oncology, American Academy of Neurology Member, Society for Neuro-Oncology 1998-present Member, American Society of Clinical Oncology 1999-present Member, American Association for Cancer Research 2005-present Member, American Society of Hematology 2010-present Member, CALGB 2011-present Member, American Neurological Association Grant Review Activities: 2005 Ad Hoc Member, Developmental Therapeutics Study Section National Cancer Institute 2006-2007 Ad Hoc Member National Institute of Biomedical Imaging and Bioengineering 2006 Ad Hoc Member Clinical Oncology Study Section National Cancer Institute 2007 Ad Hoc Member IRG – Subcommittee A Cancer Centers National Cancer Institute Tracy T. Batchelor 4/29/20175 2007-2011 Chartered Member Clinical Oncology (CONC) Study Section Oncological Sciences Integrated Review Group National Cancer Institute 2008 Chair Pediatric Brain Tumor Consortium Review Panel National Cancer Institute 2009-2014 External Advisory Board Member T32 (Friedman, PI) Research Training in Neuro-Oncology Duke University 2010-present Preferred Reviewer Italian Association for Cancer Research 2010-present Expert Reviewer Swiss National Science Foundation Editorial Activities: Editorial Boards 2014-present Editorial Board Cancer 2004-2006 2010-2014 Editorial Board Neuro-Oncology 2006-present Editorial Board Editor, Neuro-Oncology Section Oncologist 2008-2013 Editorial Board Journal of Clinical Oncology Ad Hoc Reviewer Annals of Neurology, Annals of Oncology, Blood, Cancer, Cancer Cell, Clinical Cancer Research, Clinical Lymphoma and Myeloma, European Journal of Cancer, Journal of Clinical Oncology, Journal of Neuroimaging, Journal of Neuro-Oncology, Journal of Neurosurgery, Lancet, Lancet Neurology, Lancet Oncology, Leukemia and Lymphoma, Nature Clinical Practice Oncology, Neurology, Neurology India, Neuro-Oncology, New England Journal of Medicine, Ophthalmology, Surgical Neurology, Science Translational Medicine Honors and Prizes 1986 Phi Beta Kappa Emory University - 1986 Alpha Epsilon Delta Emory University - 1987-1988 Rasmussen Scholarship Emory University - 1990 Kibler Award Emory University Top senior medical student in Neurology Tracy T. Batchelor 4/29/20176 1993-1994 Chief Resident in Neurology Massachusetts General Hospital - 2002 Preuss Award in Neuro-Oncology American Academy of Neurology Annual award to best young investigator in neuro-oncology 2007 Team Science Award Clinical Research Day Massachusetts General Hospital Annual award to best team science project in MGH research community 2007 Douglas Award Division of Hematology-Oncology Massachusetts General Hospital Annual award to best research paper in division 2008 Visiting Professor Department of Neurology Mayo Clinic 2008 Award for Excellence in Neuro-Oncology Colorado Neurological Institute 2010 Award for Adult Clinical Society for NeuroResearch Oncology/National Brain Tumor Society Award for best adult clinical research project presented at the annual SNO meeting 2011 Gary Lichtenstein Humanitarian Award Annual award to outstanding researcher in neuro-oncology Voices Against Brain Cancer Foundation - Report of Funded and Unfunded Projects Funding Information Current Funding 2013 – 2018 PI National Cancer Institute 1P50CA165962-01 (SPORE) $11,500,000 “Targeted Therapies for Glioma” The major goal of this multi-institutional, multi-disciplinary program is to identify effective targeted therapeutics in molecular subsets of glioblastoma by leveraging multiple projects, cores, a developmental award and a career award program. 2006-2013 PI National Cancer Institute 1R13CA124293-01 $25,000 “International PCNSL Collaborative Group” The major goal of this study is to support the PCNSL bi-annual, international collaborative group meeting. The agenda is to review clinical trials, review status of IPCG projects, and to review new project proposals. 2007-2017 PI National Cancer Institute 5K24CA125440A “Clinical and Molecular Studies of Novel Therapeutics in Malignant Brain Tumors” Tracy T. Batchelor $873,263 4/29/20177 The major goal of this project is to provide support for my clinical and translational studies of novel therapeutic agents in malignant brain tumors. I currently serve as principal investigator for several local national studies with extensive correlative substudies involving imaging and biospecimen collection. 2007-2018 PI National Cancer Institute $1,779,827 1R01CA129371-01 “AZD2171 and chemoradiation for newly diagnosed glioblastoma” The major goal of this project is to apply imaging and biomarker methods to patients with newly diagnosed glioblastoma treated with a novel pan-VEGF inhibitor. My role on this study is providing leadership and supervision of all aspects of the clinical trial. 2008-2016 PI 1992-2014 Co-I 2009-2014 Co-PI 2013-2016 Co-Leader, Brain Caner National Cancer Institute $2,420,000 5K12CA90354-02 “Training Program in Nervous System Tumors” The major goal is to create a multidisciplinary research training program in neuro-oncology and to train physician-scientists capable of providing a critical bridge between brain tumor biology and experimental therapeutics. My role on this grant is provide overall administrative leadership, recruitment and supervision of faculty, trainees and the individual training programs. National Cancer Institute 1R01CA117079-02 (Louis) “Toward a molecular classification of gliomas” The major goal of this project is to analyze human astrocytomas for genetic alterations and correlate these changes with clinicopathological parameters. National Cancer Institute 1R01CA137254-01A1 (Sorensen) “Quantitative MR-PET for therapy assessment in glioma” The major goal of this project is to develop improved quantitative MR-PET for use in human cancer patients by forming an academic-industrial partnership, joining academic imaging scientists and clinicians at MGH with technology experts at Siemens Medical Solutions. National Cancer Institute 5P30 CA006516-49 (Benz) “DF/HCC Comprehensive Cancer Center” Dana Farber/Harvard Cancer Center (DF/HCC), an NCI-designated comprehensive cancer center, is an innovative collaboration between seven participating institutions. The primary goal of the Brain Cancer program is to promote collaborative interactions that will lead to new approaches to brain cancer diagnosis and treatment. 2009-2014 DF/HCC Site PI National Cancer Institute “Adult Brain Tumor Consortium” The major goal of this project is to conduct multi-center, early phase trials in adults with gliomas. 2010-2015 PI Ivy Consortium “Ivy Brain Tumor Trials Consortium” The major goal of this project to lead the MGH effort in the multicenter Ivy brain tumor trials consortium to conduct novel clinical trials of targeted therapeutics in targeted glioblastoma subpopulations 1999-present Director Simches Endowed Fund for Brain Tumor Research Molecular Classification Brain Tumors The major objective of this project is support molecular and clinical studies of gliomas including the identification of predictive and prognostic biomarkers. I supervise the entire program including supported research personnel in the clinical center and the laboratory 2002-present Director Simches Scholars Fund Neuro-Oncology Junior Neuro-Oncology Endowment Faculty Support Fund Tracy T. Batchelor 4/29/20178 The major objective of this program is to provide critical bridging support for physician-investigators who are making the transition from trainee to junior faculty at MGH. Past Funding 1998-2000 Recipient National Cancer Institute T32 Training Program in Cancer Epidemiology (Nancy Mueller) This is a training grant in cancer epidemiology at Harvard School of Public Health. I was a trainee on this grant for one year, which supported course work. 1998-2003 Co-PI National Cancer Institute U01CA-69246-02 New Approaches to Brain Tumor Therapy - A CNS consortium (Fred Hochberg) This grant supported MGH as a member of a multicenter early phase clinical trial consortium of centers dedicated to studies in glioma. My role as Co-PI for this grant during this time period included responsibility for administration and leadership of clinical trials on both an institutional and national level. 2001-2008 Co-Director 2003-2006 Consulting Investigator 2004-2008 PI 2005-2008 PI 2007-2008 PI National Cancer Institute 5K12CA90354-02 Training Program in Nervous System Tumors (Robert Martuza) This grant supports a training program in neuro-oncology for trainees pursuing translational brain tumor investigations and careers in academic medicine. In my role as Co-Director I was responsible for most of the administrative aspects of the training program as well as recruitment and mentoring of K12 trainees. National Cancer Institute 2R01CA75971-06A1 Statistical Methods for Analysis of Failure Time Data” (Rebecca Betensky) This is a grant that supported an investigator developing novel methods to analyze time to failure in multiple clinical settings including neuro-oncology. My role on this grant was to provide clinical expertise and data from clinical trials to complement the statistical work conducted by Dr. Betensky. National Cancer Institute $232,882 U01CA69246-02 New Approaches to Brain Therapy – A CNS Consortium This grant supports MGH as a member of a multicenter early phase clinical trial consortium of centers dedicated to studies in glioma. My role as PI for the grant included all administrative elements of the grant as well as leadership of all clinical trials and management of all supported personnel. National Cancer Institute $390,359 1R21CA117079-01 A phase 2 study of AZD2171 for recurrent Glioblastoma The major goal of this proposal is to assess the anti-angiogenic effect of AZD2171 through correlative studies using cellular, molecular and imaging parameters. My role included overall leadership, management of the phase II clinical trial, coordination of all collaborating investigators and supervision of personnel supported by the grant. SAIC-Frederick Inc $25,000 26XS263 Correlative studies for clinical protocol P7105 (Phase II study of AZD2171 in patients with recurrent glioblastoma) The major goal of this grant was to support the correlative studies contained in the clinical trial accompanying the concurrent R21 grant listed just above. 2010-2011 PI Voices Against Brain Cancer Foundation “Correlative studies for a phase II trial of PF00299804, an irreversible EGF receptor tyrosine kinase inhibitor for patients with EGFR-amplified, recurrent glioblastoma” The major goal of this project is to perform correlative tissue and blood studies in patients enrolled in a phase II clinical trial of PF00299804. Tracy T. Batchelor 4/29/20179 2006-2011 Co-PI National Cancer Institute 5R01CA114205-03 (Michaud) “Allergies, genetic susceptibility and adult glioma risk” The major goal of this project is to examine hypotheses related to allergies and genetic susceptibility by studying the etiology of gliomas. Tracy T. Batchelor 4/29/201710 Report of Local Teaching and Training Teaching of Students in Courses 1998, 2003 Introduction to Clinical Epidemiology (Harvard School of Public Health) Graduate Students Seminar Leader 1 Seminar (4 hours preparation)_ 2000-2004 Epidemiology of Neurologic Diseases (Harvard School of Public Health) Graduate Students Lecturer 1 Lecture (4 hours preparation) 2002-2004 Neurobiology of Disease (Harvard Medical School) Graduate Students Lecturer 1 Lecture (4 hours preparation) 2009 Tumor Pathophysiology and transport phenomena: a systems biology approach HST 525J (Massachusetts Institute of Technology) Graduate Students Lecturer 1 Lecture (4 hours preparation) 2010 - present Doctoral Advisory Committee Pre-Doctoral Student Committee Member (Theresa Peterson) 2 meetings per year Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs) 2001 Clinical Research Methods in Neurology (Partners Neurology Residency) Neurology Residents Lecturer 1 Lecture (2 hours preparation) 2006-2011 Hematology/Oncology Fellow Lecture Series (Dana-Farber/Harvard Fellowship) Heme/Onc Fellows Lecturer 1 Lccture (2 hours preparation) 2006-present Steele Laboratory Angiogenesis Course (Massachusetts General Hospital) Post-doctoral fellows Lecturer 1 Lecture (2 hours preparation) 2006-present Neuro-Oncology Fellow Lecture Series (Dana-Farber/Harvard Fellowship) Neuro-Oncology Fellows Lecturer 2 Lectures (4 hours preparation) 2008-present Neurology Resident Neuroscience Lecture Series (Partners Neurology Residency) Neurology Residents Lecturer 1 Lecture (2 hours preparation) 2010 Pankaj Agarwalla Reader/Oral Examiner 1 session (2 hours preparation and 2 hour meeting) HMS Honors Examination 2012 Lecturer 1 session (2 hours preparation and 1 hour meeting) Radiation Oncology Resident Lecture Series (Massachusetts General Hospital) Radiation Oncology residents Clinical Supervisory and Training Responsibilities 1996-2000 Attending/Supervising neurologist Neurology Ambulatory Clinic, 8 sessions per year Supervision of 3 residents per session 4 hours/week for 8 weeks 1996-2006 Director, Neuro-Oncology Fellowship Program Supervision/teaching of all neuro-oncology fellows 4 hours/week for 52 weeks Tracy T. Batchelor 4/29/201711 Responsible for fellow recruitment and career development Responsible for Partners accreditation of training program Responsible for expansion of program to Dana-Farber 1996-present Attending/Supervising neuro-oncologist Dedicated inpatient neuro-oncology service of ~60-80 inpatients each assigned month Supervision of 3-6 fellows and occasional rotating students, residents, fellows over 12 weeks 30 hours/week for 12 weeks 1996-present Attending neurologist, Brain Tumor Clinic 12-18 hours/week for 52 weeks Supervise neuro-oncology fellows, neurology residents and occasional HMS students rotating in my clinic session Formally Supervised Trainees Post-Graduate, Pre-Doctoral Trainees Years Names and Degrees Current Position 1999-2001 Nicole Piscatelli, M.D. (University of Massachusetts) General Surgeon, Phoenix, Arizona 2003-2005 Molly Dorfman, B.A. (Wellesley), M.D., M.P.H. (Tulane) Critical Care Pediatric Medicine Fellow, University of Washington Medical Center, Seattle, Washington 2004-2005 Whitney Nugent, B.S. (University of North Carolina), M.D. (Boston University) Pediatrician, Charlotte, North Carolina 2005-2006 Kristin Nierenberg, B.S. (Tufts), M.D. (Harvard) Family Medicine, Swedish Medical Center 2005-2007 Anne Newcomer, B.S. (Williams), M.D. Case Western Anesthesiology Resident, UCSF 2006-2008 Jessica Provo, B.S. (McGill) Graduate Student, Boston University 2007-2008 Peter Ryg, B.S. (Brown), M.D., Thomas Jefferson University Obstetrics Resident, Thomas Jefferson University Tracy T. Batchelor Description of supervision and accomplishments Supervised Ms. Piscatelli in design and implementation of our patient research database and several chapters. Supervised Ms. Dorfman as our data manager and on clinical-molecular phenotype project which led to peerreviewed publication Supervised Ms. Nugent as our data manager and in clinical research project in CNS lymphoma which resulted in peer-reviewed publication Supervised Ms. Nierenberg as our data manager and in clinical research project in CNS lymphoma, which resulted in peer-reviewed publication. Supervised Ms. Newcomer as our data manager and in preparation of chapter for textbook Supervised Ms. Provo as our data manager and on ongoing project involving radiation for glioblastoma patients Supervised Mr. Ryg as our data manager and in review of vasogenic brain edema published in peer-reviewed journal 4/29/201712 2008-2011 Daphne Wang, B.S. (MIT) Medical Student, New York Medical College 2011-present Daniel Yang, B.S. (Brown) Research Assistant 2014-present Corey Gill, B.S. (Boston University) Research Assistant Supervised Ms. Wang as our data manager on project involving prognostic markers in glioblastoma Post-Doctoral Resident and Neuro-Oncology Fellowship Trainees Years Name and degrees Current Position Description of supervision and accomplishments 1997-1999 Nicholas Avgeropoulos, M.D. Director of Neuro-Oncology, Florida Hospital, Orlando, Florida Supervised clinical training and development, implementation, execution and scientific presentation of a phase I/II trial of oxaliplatin for glioblastoma 1997-1998 Michael Platten, M.D., Ph.D. Neuro-Oncologist, University of Heidelberg, Heidelberg, Germany Supervised clinical project which led to original, published report of chorea as a paraneoplastic complication of lymphoma 1996-1998 Denise Damek, M.D. Staff Neuro-Oncologist and Associate Professor of Neurology, University of Colorado Health Sciences Center Supervised clinical training 1998-2000 Roberto Ciordia, M.D. Neurologist/Neuro-Oncologist, Bilbao, Spain Supervised clinical training and research project which led to publication of a report of methotrexate for intraocular lymphoma 1999-2003 Suriya Jeyapalan, M.D. Director, Division of NeuroOncology, Rhode Island Hospital; Instructor of Neurology, Brown University School of Medicine Supervised clinical training and fellow preparation and publication of review on CNS metastases 2000-2002 Joachim Baehring, M.D. Staff Neuro-Oncologist, Yale-New Haven Hospital; Director, Yale Brain Tumor Center; Associate Professor of Neurology, Yale Supervised clinical training and research project which resulted in publication of institutional experience with malignant peripheral nerve sheath tumors 2000-2002 Benjamin Lawler, M.D. Staff Neuro-Oncologist, Marshfield Clinic, Marshfield, Wisconsin (former K12 trainee) Supervised clinical training and research project which led to scientific presentation of phase II Tracy T. Batchelor 4/29/201713 study of high dose methotrexate for primary CNS lymphoma 2002-2004 Scott Plotkin, M.D., Ph.D. Associate Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology, MGH; Associate Professor of Neurology, HMS (former K12 trainee) Supervised clinical training, recruitment onto medical staff and numerous research projects including pilot study of sunitinib for recurrent glioblastoma, served on K12 mentoring committee 2002-2004 Alfredo Voloschin, M.D. Staff Neuro-Oncologist, Emory University Hospital; Assistant Professor of Hematology and Oncology, Emory University (former K12 trainee) Supervised clinical training and fellow research project which led to publication of a phase 2 study of topotecan for recurrent primary CNS lymphoma, served on K12 mentoring committee 2002-2005 Alice Brown, M.D., Ph.D. Neurologist, Boston, MA (former K12 trainee) Supervised clinical training 2003-2005 Jay Zhu, M.D., Ph.D. Director, Neuro-Oncology, Texas Medical Center; Associate Professor of Neurosurgery, University of Texas Health Sciences Center, Houston Supervised clinical training and fellow research project that led to publication of paper on high-dose methotrexate for elderly patients with primary CNS lymphoma 2003-2006 Maciej Mrugala, M.D., Ph.D. Director, Division of NeuroOncology, Associate Professor of Neurology, Alex Spence Endowed Chair in Neuro-Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington Supervised clinical training and fellow research project on elderly patients with primary CNS lymphoma which was published 2003-2004 Santosh Kesari, M.D., Ph.D. Director, Neuro-Oncology Program, Moores Cancer Center, Professor of Neuroscience, University of California, San Diego (former K12 trainee) Supervised clinical training and published fellow review of leptomeningeal metastases 2003-2004 Paul Nguyen, M.D. Staff Radiation Oncologist, DFCI; Associate Professor of Radiation Oncology, HMS Supervised resident research project that led to publication of a project on whole brain irradiation as salvage therapy for primary CNS lymphoma 2004-2005 Jan Drappatz, M.D. Associate Director of Adult NeuroOncology, University of Pittsburgh, Associate Professor of Neurology, University of Pittsburgh Supervised as visiting medical student, clinical training as fellow and fellow project on neurological complications of plasma cell dyscrasias that was published 2004-2005 Helen Shih, M.D. Staff Radiation Oncologist, MGH; Associate Professor of Radiation Supervised resident research project that led to publication of paper on molecular determinants Tracy T. Batchelor 4/29/201714 Oncology, HMS (former K12 trainee) of radiation response in glioblastoma 2004-2005 Ricky Tong, M.D, Ph.D. Radiology Resident, UCSF Supervised student involvement in phase 2 study of AZD2171 for glioblastoma that was published 2004-2006 William T. Curry, Jr., MD Director, Neurosurgical Oncology, MGH; Associate Professor of Neurosurgery, HMS (former K12 trainee) Served on K12 mentoring committee during his fellowship 2005-2006 Manish Aghi, M.D. Staff Neurosurgeon, UCSF, San Francisco, California Supervised part of resident research project that led to publication of paper on EGFR amplification as predictor of imaging features in glioblastoma 2005-2006 April Eichler, M.D. Staff Neuro-Oncologist, MGH; Assistant Professor of Neurology, HMS Supervised clinical training, recruitment onto professional staff, mentored for successful R21 grant application 2005-2006 Jeanine Grier, M.D. Staff Neurologist, Emerson Hospital, Concord, MA Supervised clinical training and published review on low-grade gliomas and CNS metastases 2005-2009 Milan Chheda, M.D. Staff Neuro-Oncologist, Memorial Sloan-Kettering Cancer Center; Instructor of Neurology, Cornell Medical College (former K12 trainee) Supervised clinical training, recruitment onto professional staff and clinical trial that is currently open entitled, phase I Study of ZD6474 + rapamycin in recurrent glioblastoma, served on K12 mentoring committee 2006-2009 Andrew Chi, M.D., Ph.D. Staff Neuro-Oncologist, MGH; Assistant Professor of Neurology, HMS (former K12 trainee) Supervised clinical training and research project that led to a clinical trial of an irreversible EGFR kinase inhibitors for glioblastoma, recruited onto professional staff, served on K12 mentoring committee 2006-2009 Elizabeth Gerstner, M.D. Staff Neuro-Oncologist, MGH; Assistant Professor of Neurology, HMS; (former K12 trainee and HMS T32 Scholars in Clinical Science trainee) Supervised clinical training and research projects that have led to multiple publications for CNS lymphoma and glioblastoma, mentored for current K23 application, recruited onto professional staff, served on K12 mentoring committee and T32 thesis committee Tracy T. Batchelor 4/29/201715 2006-2007 Andrew Norden, M.D. Staff Neuro-Oncologist, DFCI Assistant Professor of Neurology, HMS Supervised fellow for published review of Reversible Posterior Leukoencephalopathy 2008-present Eudocia Quant, M.D. Staff Neuro-Oncologist, DFCI Instructor of Neurology, HMS (former K12 trainee) Supervised clinical training and Co-supervised fellow research project regarding genetic markers of prognosis in gliomas that has led to presentation at scientific meeting, serve on K12 mentoring committee 2009-present Jorg Dietrich, M.D., Ph.D. Staff Neuro-Oncologist, MGH; Assistant Professor of Neurology, HMS (former K12 trainee) Supervised clinical training and published review of angiogenesistargeting drugs for glioblastoma, recruited onto professional staff, serve on K12 mentoring committee 2009-present Priscilla Brastianos, M.D. Staff Neuro-Oncologist, MGH; Instructor of Medicine, HMS (former K12 trainee) Supervised fellow on primary research project, intrathecal bevacizumab for leptomeningeal metastases 2009-present Christine LuEmerson, M.D. Staff Neuro-Oncologist, Maine Medical Center (former K12 trainee) Supervised clinical training and co-supervising project K12 project on patterns of glioma progression post-VEGF therapy 2009-2010 Ryan Merrell, M.D. Staff Neuro-Oncologist, Evanston Hospital Supervised clinical training and on chapter writing project for textbook 2009-2010 Erik Uhlmann, M.D. Staff Neuro-Oncologist, Beth Israel Deaconess Medical Center Instructor of Neurology, HMS Supervised clinical training 2010-2011 Wesley Clark, M.D., Ph.D. Staff Neuro-Oncologist, Vanderbilt University Medical Center, Assistant Professor of Neurology, Vanderbilt University Supervised fellow on clinical training rotations, supervised research project on chemotherapy complications 2010-present Shota Tanaka, M.D. Staff Neurosurgical Oncologist, University of Tokyo Supervised fellow on clinical training rotations, supervised fellow in development of orthotopic glioma models from neurospheres 2010-2011 Mik Rinne, M.D., Ph.D. Staff Neuro-Oncologist, DanaFarber Cancer Institute, Instructor of Neurology, HMS (former K12 trainee) Supervised fellow on clinical training rotations, K12 mentoring committee Tracy T. Batchelor 4/29/201716 2011-present Jennie Taylor, M.D. Assistant Professor, University of California, San Francisco Supervising fellow on clinical training rotations, K12 mentoring committee 2011-2013 Tara Benkers, M.D. Staff Neuro-Oncologist, Swedish Medical Center, Seattle Supervising fellow on clinical training rotations 2012-present Isabel Arrillaga, M.D., Ph.D. Staff Neuro-Oncology, MGH; Instructor of Neurology, HMS (former K12 trainee) Supervising fellow on clinical and training rotations 2012-present Soma Sengupta, M.D., Ph.D. Fellow, MGH/DFCI, K12 trainee Supervising fellow on clinical and training rotations 2013-2014 Jasmin Jo, M.D. Neurology Resident, University of Virginia Supervising fellow on clinical and training rotations 2013-present Justin Jordan, M.D. Fellow, MGH/DFCI, K12 Trainee Supervising fellow on clinical and training rotations 2014-present Ashley Plant, M.D. Fellow, Pediatric Oncology, CHMC, K12 Trainee K12 Mentoring Committee 2014-present Deborah Forst, M.D. Fellow, Neuro-Oncology Supervising fellow on clinical rotations 2014-present Martha Neagu, M.D., Ph.D. Fellow, Neuro-Oncology Supervising fellow on clinical rotations 2014-present Sylvia Eisele, M.D. Fellow, Neuro-Oncology Supervising fellow on clinical rotations Formal Teaching of Peers 1997-2006 Leptomeningeal Metastases Tumors of the Nervous Systems Boston, MA 1 lecture each year Brigham and Women’s Hospital CME Course 1998, 2001-2003 Primary brain tumors, CNS lymphoma 2009 Intensive Review of Neurology Boston, MA 1 lecture each year listed Department of Neurology, HMS CME Course 2004 Neuro-Oncology Summary Best of ASCO Meeting Boston, MA 1 lecture American Society of Clinical Oncology 2009-present Anti-Angiogenic Therapy Annual Neuroradiological Review Boston, MA 1 lecture Department of Radiology, HMS CME Course 2010-present Contemporary management of glioblastoma Neuroradiology Seminar Series Boston, MA 1 lecture Division of Neuroradiology, HMS Tracy T. Batchelor 4/29/201717 Local Invited Presentations 1996 Intracranial Hypotension Department of Neurosurgery Boston, MA Massachusetts General Hospital Neurosurgical Grand Rounds Department of Neurosurgery 1998 Lymphomas in peripheral nerves Department of Neurosurgery Boston, MA Massachusetts General Hospital Neurosurgical Grand Rounds Department of Neurosurgery 1998 Neurosarcoidosis Department of Neurosurgery Massachusetts General Hospital Neurosurgical Grand Rounds Department of Neurosurgery Boston, MA 1999 Molecular markers of prognosis in gliomas Department of Neurology Boston, MA Massachusetts General Hospital Neurology Grand Rounds Department of Neurology 2000 Advances in Primary CNS Lymphoma Department of Neurology Boston, MA Massachusetts General Hospital Neurology Grand Rounds Department of Neurology 2002 Primary CNS Lymphoma Department of Neurosurgery Boston, MA Massachusetts General Hospital Neurosurgical Grand Rounds Department of Neurosurgery 2002 Epidemiology of Primary Brain Tumors Department of Biostatistics Boston, MA Harvard School of Public Health Neurostatistics Seminar Department of Biostatistics 2003 New England Journal CPC Department of Neurology Boston, MA Massachusetts General Hospital Neurology Grand Rounds New England Journal of Medicine 2004 Evolution of therapy for primary CNS lymphoma Department of Adult Oncology Boston, MA Dana-Farber Cancer Institute Dana-Farber/Partners Cancer Center Grand Rounds 2006 Update on the management of glioblastoma Department of Neurosurgery Boston, MA Massachusetts General Hospital Neurosurgical Grand Rounds Department of Neurosurgery 2006 Management of glioblastoma MGH Cancer Center Boston, MA Massachusetts General Hospital MGH Cancer Center Grand Rounds MGH Cancer Center 2007 Phase II trial of AZD2171 for recurrent glioblastoma MGH Cancer Center Grand Rounds MGH Cancer Center Boston, MA MGH Cancer Center Massachusetts General Hospital 2008 Primary CNS Lymphoma Division of Neuro-Oncology Boston, MA Dana-Farber Cancer Institute Tracy T. Batchelor Neuro-Oncology Seminar Division of Neuro-Oncology 4/29/201718 2008 Angiogenesis in Glioblastoma Division of Neuroradiology Boston, MA Massachusetts General Hospital 2010 CNS Lymphomas Division of Hematology-Oncology Beth Israel Deaconess Medical Center Boston, MA 2010 Angiogenesis as a therapeutic target Division of Neuro-Oncology Boston, MA Brigham and Women’s Hospital Neuroradiology Seminar Division of Neuroradiology Hematology-Oncology Series Neuro-Oncology Seminar Series 2011 NEJM CPC (with David Louis, Greg Sorensen) Massachusetts General Hospital Cancer Center Boston, Massachusetts Grand Rounds 2012 ASCO Presentations Department of Neurosurgery Massachusetts General Hospital Boston, Massachusetts Grand Rounds Report of Regional, National and International Invited Teaching and Presentations Regional 1999 Nervous System Lymphoma Boston University Boston, MA Neurology Grand Rounds Department of Neurology 2002 Primary CNS Lymphoma Rhode Island Hospital Providence, RI Medicine Grand Rounds Department of Medicine 2003 Leptomeningeal Metastases Dartmouth-Hitchcock Medical Center Lebanon, NH Hematology/Oncology Grand Rounds Division of Hematology-Oncology 2003 Management of Leptomeningeal Metastases Tufts Medical Center Boston, MA Hematology/Oncology Grand Rounds Division of Hematology-Oncology 2005 Leptomeningeal Metastases Lahey Clinic Burlington, MA Hematology-Oncology Seminar Division of Hematology-Oncology 2006 Contemporary management of glioblastoma Tufts Medical Center Boston, MA Neurology/Neurosurgery Grand Rounds Department of Neurosurgery 2007 Anti-VEGF therapy for brain tumors Angiogenesis Foundation, 5th International Conference Cambridge, MA Lecture Angiogenesis Foundation 2008 Angiogenesis-targeting therapy for glioblastoma Tufts Medical Center Boston, MA Hematology-Oncology Grand Rounds Division of Hematology-Oncology Tracy T. Batchelor 4/29/201719 2008 Angiogenesis-targeting therapy for glioblastoma Boston University School of Medicine Boston, MA Neurology Grand Rounds Department of Neurology 2008 Endpoints and markers for anti-angiogenic therapy in malignant gliomas Angiogenesis Foundation, Judah Folkman Conference Cambridge, MA Lecture 2009 Update on management of CNS lymphoma Mugar Cancer Center, Cape Cod Hospital Hyannis, MA Oncology Grand Rounds Mugar Cancer Center 2009 Contemporary management of glioblastoma St. Anne’s Hospital Fall River, MA Cancer Center Grand Rounds St. Anne’s Hospital Cancer Center 2010 CNS Lymphoma Tufts University School of Medicine Boston, Massachusetts Neuroscience Grand Rounds 2011 Update on Glioblastoma Tufts University School of Medicine Boston, Massachusetts Cancer Grand Rounds 2011 Update on Glioblastoma University of Massachusetts Medical School Worcester, Massachusetts Neurology Grand Rounds 2010-present Glioblastoma HMS Postgraduate Course in Neuroradiology Boston, Massachusetts CME Lecture 2012, 2013 Neuro-Oncology HMS Post-Graduate Course on Cancer Medicine Fairmont Copley Plaza Boston, Massachusetts CME Lecture 2013 Update on Glioblastoma Newton-Wellesley Hospital Newton, Massachusetts Medicine Grand Rounds 2013 Anti-angiogenic therapy for glioblastoma Tufts University School of Medicine Boston, Massachusetts Cancer Center Grand Rounds 2001 New directions in neuro-oncology American Society of Clinical Oncology Annual Meeting San Francisco, CA Lecture American Society of Clinical Oncology 2001 Neoplastic Meningitis Thomas Jefferson University Philadelphia, PA Oncology Seminar Series Division of Hematology-Oncology Angiogenesis Foundation National Tracy T. Batchelor 4/29/201720 2001 Neoplastic Meningitis Fox Chase Cancer Center Philadelphia, PA Hematology-Oncology Seminar Fox-Chase Cancer Center 2001 Neoplastic Meningitis Hahnemann University Philadelphia, PA Hematology-Oncology Seminar Division of Hematology-Oncology 2002 Primary CNS lymphoma St. Luke’s-Roosevelt Medical Center New York, New York 1st Annual Edwin Teich Memorial Lecture Division of Hematology-Oncology 2002 Advances in the management of CNS lymphoma Roswell Park Cancer Institute Buffalo, NY Medicine Grand Rounds Department of Medicine 2002 Prospects for a phase III trial in CNS lymphoma 8th Annual Blood Brain Barrier Consortium Meeting Portland, OR Lecture Blood Brain Barrier Consortium 2002 Leptomeningeal metastases SUNY-Stony Brook School of Medicine Stony Brook, NY Hematology-Oncology Seminar Division of Hematology-Oncology 2002 Leptomeningeal metastases North Shore University Hospital Manhasset, NY Hematology-Oncology Seminar Division of Hematology-Oncology 2002 Primary CNS lymphoma Cleveland Clinic Cleveland, OH Hematology-Oncology Grand Rounds 2002 Primary CNS lymphoma University of Pittsburgh School of Medicine Pittsburgh, PA Neuro-Oncology Seminar Division of Neuro-Oncology 2002 Leptomeningeal metastases SUNY-Syracuse School of Medicine Syracuse, NY Hematology-Oncology Seminar Division of Hematology-Oncology 2002 Primary CNS lymphoma University of California, San Diego San Diego, CA Neurology Grand Rounds Department of Neurology 2003 Leptomeningeal metastases Westchester Medical Center Valhalla, NY Hematology-Oncology Grand Rounds Division of Hematology-Oncology 2004 Management of leptomeningeal metastases New York-Presbyterian Hospital New York, NY Hematology-Oncology Grand Rounds Division of Hematology-Oncology 2004 Lymphomatous meningitis Memorial Sloan-Kettering Cancer Center New York, NY Lymphoma Conference Lymphoma Service Tracy T. Batchelor 4/29/201721 2004 Management of leptomeningeal metastases Washington Hospital Medical Center Washington, D.C. Hematology-Oncology Grand Rounds Division of Hematology-Oncology 2004 Evolution of therapy for primary CNS lymphoma University of Alabama, Birmingham Birmingham, AL Neurology-Neurosurgery Grand Rounds Department of Neurology 2004 Contemporary management of glioblastoma University of Texas, San Antonio San Antonio, TX Neurology Grand Rounds Department of Neurology 2004 Management of leptomeningeal metastases Scripps Clinical Hematology and Oncology Conference La Jolla, CA CME course lecture Scripps Cancer Institute 2005 Leptomeningeal metastases University of Pennsylvania Philadelphia, PA Oncology Grand Rounds Division of Oncology 2005 Primary CNS lymphoma Emory University School of Medicine Atlanta, GA Neuro-Oncology Conference Division of Neuro-Oncology 2005 Contemporary management of glioblastoma Medical College of Georgia Augusta, GA Neurosurgery Grand Rounds Department of Neurosurgery 2005 Primary CNS lymphoma University of Virginia Charlottesville, VA Neurology Grand Rounds Department of Neurology 2005 Summary of 2005 Neuro-Oncology Abstracts American Society of Clinical Oncology Annual Meeting Orlando, FL Lecture American Society of Clinical Oncology 2005 Supportive Care of Brain Tumor Patients Advances in Neuro-Oncology New York, NY Lecture Department of Neurology Memorial Sloan-Kettering Cancer 2005 Primary CNS Lymphoma Pan Pacific Lymphoma Conference Kauai, HI CME course lecture University of Nebraska 2005 What’s new for primary CNS tumors Oncology World Congress New York, NY CME lecture Imedex 2006 CNS metastases University of Washington Seattle, WA Neurology Grand Rounds Department of Neurology 2006 Neurotoxicity of anti-cancer therapeutics University of Nebraska Medical Center Hematology-Oncology Seminar Division of Hematology-Oncology Tracy T. Batchelor 4/29/201722 Omaha, NE 2006 Contemporary management of malignant gliomas University of Nebraska Medical Center Omaha, NE Medicine Grand Rounds Department of Medicine 2006 Contemporary management of glioblastoma Oregon Health Sciences University Portland, OR Neurology Grand Rounds Department of Neurology 2006 Primary CNS lymphoma American Society for Therapeutic Radiation Oncology Annual Meeting Philadelphia, PA Lecture American Society for Therapeutic Oncology 2007 Current management of primary CNS lymphoma American Society of Clinical Oncology Annual Meeting Chicago, IL CME lecture American Society of Clinical Oncology 2007 Primary CNS lymphoma Pan Pacific Lymphoma Conference Maui, HI CME lecture University of Nebraska 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor for recurrent glioblastoma American Association for Cancer Research Annual Meeting Los Angeles, CA Plenary Lccture American Association for Cancer Research 2007 Angiogenesis-targeting therapy for glioblastoma American Association for Cancer Research Annual Meeting Los Angeles, CA CME Lecture American Association for Cancer Research 2007 Neurology Grand Rounds Department of Neurology AZD2171, a pan VEGF receptor tyrosine kinase inhibitor for recurrent glioblastoma Emory University Atlanta, GA 2007 Primary CNS lymphoma Advances in Neuro-Oncology Course University of Chicago Chicago, IL CME lecture Division of Neuro-Oncology 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor for recurrent glioblastoma American Society of Clinical Oncology Annual Meeting Chicago, IL Lecture 2007 Update on the management of primary CNS lymphoma Columbia University New York NY Hematology-Oncology Grand Rounds Division of Hematology-Oncology 2007 Leptomeningeal metastases Fox Chase Cancer Center Philadelphia, PA Hematology-Oncology Grand Rounds Tracy T. Batchelor American Society of Clinical Oncology 4/29/201723 2007 Update on glioblastoma AstraZeneca Science Day Wilmington, DE Lecture AstraZeneca 2007 AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor for recurrent glioblastoma Emory University School of Medicine Atlanta GA Oncology Seminar 2007 AZD2171 in glioblastoma National Cancer Institute Early Drug Development Meeting Bethesda, MD Lecture National Cancer Institute 2008 Primary CNS lymphoma Pan Pacifica Lymphoma Conference Hilo, HI CME lecture University of Nebraska 2008 Contemporary management of malignant gliomas Future Directions in Hematology-Oncology Kiawah Island, SC CME lecture Emory University 2008 CNS lymphoma American Academy of Neurology Annual Meeting Chicago, IL CME lecture American Academy of Neurology 2008 Phase II trial of cediranib in recurrent glioblastoma American Association for Cancer Research Annual Meeting San Diego, CA Plenary Presentation American Association for Cancer Research 2008 Neurology Grand Rounds Phase II trial of cediranib, an oral pan-VEGF inhibitor, in patients with recurrent glioblastoma Winship Cancer Institute Mayo Clinic Rochester, MN Department of Neurology 2008 New therapies for glioblastoma Colorado Neurological Institute Denver, CO Neurology Grand Rounds Brain Tumor Program 2008 Contemporary management of glioblastoma University of Utah Salt Lake City, UT Neurosurgical Grand Rounds Department of Neurosurgery 2008 Angiogenesis-targeting therapy for glioblastoma Huntsman Cancer Institute Salt Lake City, UT Invited Seminar Huntsman Cancer Institute 2008 Molecular markers of response and resistance to VEGFR inhibitors in brain tumors National Cancer Institute-European Organization for Research and Treatment of Cancer Annual Meeting Orlando, FL Invited Lecture National Cancer Institute 2009 Leptomeningeal Metastases American Society of Clinical Oncology Annual Meeting CME lecture American Society of Clinical Oncology Tracy T. Batchelor 4/29/201724 Orlando, FL 2009 Angiogenesis-targeting therapy for glioblastoma Dartmouth-Hitchcock Medical Center Lebanon, NH Medicine Grand Rounds Department of Medicine 2009 Angiogenesis as a therapeutic target in glioblastoma Neurology Grand Rounds New York University Department of Neurology New York, NY 2009 Update in neuro-oncology 15th Annual NOCR Meeting Las Vegas, NV CME lecture Imedex 2009 Vascular targeting in the upfront versus rccurrent tumor setting 15th Annual Blood Brain Barrier Consortium Meeting Gleneden Beach, OR Invited Lecture 2009 Contemporary management of glioblastoma Washington Hospital Washington, D.C. Oncology Grand Rounds Division of Oncology Blood Brain Barrier Consortium 2009 Angiogenesis as a therapeutic target for glioblastoma Cancer Center Grand Rounds Yale Cancer Center Yale Cancer Center New Haven, CT 2009 Angiogenesis as a therapeutic target in glioblastoma Brain Tumor Seminar Series Memorial Sloan-Kettering Cancer Center Department of Neurology New York, NY 2009 Anti-Angiogenesis Ohio State University Columbus, OH 2009 CNS Lymphomas 8th Annual International Neuro-Oncology Update Department of Neurosurgery Southern California Lymphoma Group Los Angeles, CA 2009 Update on CNS lymphoma University of Southern California Los Angeles, CA Hematology Grand Rounds Norris Cancer Center 2010 Neuro-Oncology Education Session American Academy of Neurology Annual Meeting Angiogenesis as a therapeutic target in glioblastoma Toronto, Ontario 2010 CNS lymphomas 16th Annual Blood Brain Barrier Consortium Meeting Bend, OR Panel Discussion Blood Brain Barrier Consortium 2010 Clinical investigations in CNS lymphoma University of California, San Francisco San Francisco, California Hematology/Oncology Seminar Tracy T. Batchelor 4/29/201725 2011 Primary CNS Lymphoma Yale University School of Medicine New Haven, Connecticut Neurology Grand Rounds 2011 Primary CNS Lymphoma Update Pan-Pacific Lymphoma Meeting Kaua’i Hawai’i Invited Lecture 2011 Primary CNS Lymphoma Blood Cancer Symposium Winthrop P. Rockefeller Cancer Institute, University of Arkansas Little Rock, Arkansas Invited Lecture 2012 Targeted therapies for glioblastoma Seminar Medical University of South Carolina Charleston, South Carolina Invited Lecture 2012 Invited Lecture 50th Annual American Society of Neuroradiology Meeting Decision-making after anti-angiogenic therapy: the neuro-oncologist’s perspective Symposium New York, New York 2012 The search for predictive markers to glioblastoma response versus resistance to anti-angiogenic therapies Boston, Massachusetts Invited Lecture Annual American Neurological Association Meeting 2012 CNS Lymphoma: Treatment and Prevention Chicago Illinois Invited CME Lecture American Society of Hematology Educational Symposium 2012 CNS Lymphoma: Treatment and Prevention Los Angeles, California Invited CME Lecture American Society of Hematology Educational Symposium 2013 Antiangiogenic therapy for glioblastoma Chicago, Illinois Invited Lecture American Society of Clinical Oncology Annual Meeting 2013 Challenging case studies in glioblastoma Atlanta, Georgia Invited Lecture American Society of Therapeutic Radiation Oncology Annual Meeting 2013 Is radiation needed for primary CNS lymphoma? San Francisco, California Invited Lecture Society for Neuro-Oncology Annual Meeting 2013 CNS lymphomas University of Rochester Rochester, New York Neurology Grand Rounds 2014 Anti-angiogenic therapy for glioblastoma M.D. Anderson Cancer Center Houston, Texas Brain Tumor Center Seminar Tracy T. Batchelor 4/29/201726 2014 Anti-angiogenic therapy for glioblastoma Memorial Sloan-Kettering Cancer Center New York, New York Brain Tumor Center Seminar 2014 Update in Neuro-Oncology American Academy of Neurology Annual Meeting Philadelphia, Pennsylvania Highlights in the Field 2014 2014 CNS lymphomas Albert Einstein School of Medicine Bronx, New York Neurology Grand Rounds 2014 CNS lymphomas Pan Pacific Lymphoma Conference Hilo, Hawai’i Invited CME Lecture International 2002 Primary CNS lymphoma: what are the next questions? 8th International Conference on Malignant Lymphoma Lugano, Switzerland Invited Lecture 2002 PCNSL Workshop Summary 8th International Conference on Malignant Lymphoma Lugano, Switzerland Lecture International Extranodal Study Group 2003 PCNSL Symposium International Extranodal Study Group Meeting Barcelona, Spain Lecture International Extranodal Study Group 2006 Intrathecal therapy for primary CNS lymphoma Canadian Congress of Neurological Sciences Annual Meeting Montreal, Canada Invited Lecture Canadian Congress of Neurological Sciences 2006 New treatments for primary CNS lymphoma Canadian Congress of Neurological Sciences Annual Meeting Montreal, Canada Invited Lecture Canadian Congress of Neurological Sciences 2008 Overview of cediranib REGAL Investigators Meeting Vienna, Austria Lecture AstraZeneca 2008 Management of newly diagnosed glioblastoma Neuro-Oncology Symposium Rio de Janeiro, Brazil CME lecture Strategic Edge Communications 2008 Advances in the anti-angiogenic treatment of Perspectives in CNS malignancies Berlin, Germany CME lecture Imedex 2009 Anti-angiogenic therapy for glioblastoma Neuro-Oncology Symposium Buenos Aires, Argentina CME lecture Strategic Edge Communications Tracy T. Batchelor International Extranodal Study Group 4/29/201727 2009 Update on anti-angiogenic therapy Neuro-Oncology Conference Prince of Wales Hospital, Sydney, Australia Invited Lecture 2009 Contemporary management of glioblastoma Oncology Rounds St. George Hospital, Sydney, Australia Invited Lecture 2009 Update on anti-angiogenic therapy Neuro-Oncology Conference Royal Northshore Hospital, Sydney, Australia Invited Lecture 2009 Anti-angiogenic therapy for glioblastoma Brisbane, Australia Invited Lecture 2009 Neuro-Oncology case discussions Neurology Conference Austin Hospital, Melbourne, Australia Invited participation 2009 Management of glioblastoma Neuro-Oncology Conference Christchurch, New Zealand Invited Lecture 2009 Contemporary management of glioblastoma Wellington Hospital, Wellington, New Zealand Invited Lecture 2009 CNS lymphomas Middlemore Hospital, Auckland, New Zealand Invited Lecture 2009 CNS lymphomas Blood Club Auckland, New Zealand Invited Lecture 2010 Anti-angiogenic therapy for glioblastoma 9th Annual International Neuro-Oncology Update Cortona, Italy Invited Lecture 2010 CNS lymphomas CNS Lymphoma Symposium Freiburg, Germany Invited Lectures 2010 Pediatric CNS lymphomas International Society of Pediatric Neuro-Oncology Meeting Vienna, Austria Presentation 2010 Anti-angiogenic therapy for glioblastoma Current Trends in the Management of Malignant Brain Tumors Tokyo, Japan Invited Lecture 2010 Primary CNS lymphomas Current Trends in the Management of Malignant Brain Tumors Tokyo, Japan Invited Lecture 2010 REGAL Phase III results Proferred Papers Session European Society for Medical Oncology Meeting Presentation Tracy T. Batchelor 4/29/201728 Milan, Italy 2010 REGAL Phase III results Top Scoring Abstracts Session Society of Neuro-Oncology Annual Meeting Montreal, Quebec, Canada Presentation 2010 Angiogenesis-targeting therapies for glioblastoma Neuro-Oncology Seminar Rome, Italy Invited Lecture 2011 CNS Lymphoma Update 15th Annual International Congress on Hematologic Malignancies Whistler, British Columbia, Canada Invited Lecture 2011 Angiogenesis Inhibitors for glioblastoma Invited Lecture International Symposium on Clinical and Basic Investigation for Glioblastoma Valencia, Spain 2011 VEGF inhibitors in glioblastoma EORTC-EANO Annual Meeting Bucharest, Romania Invited Lecture 2011 Oligodendrogliomas Symposium on Neuro-Oncology Taipei, Taiwan Invited Lecture 2012 Trials of anti-angiogenic therapies in the U.S. Invited Lecture 10th Annual Meeting, European Association of Neuro-Oncology Association des Neuro-Oncologues d’Expression Francaise (ANOCEF) Marseille, France 2013 Angiogenesis-Targeting Therapy for Glioblastoma Asian Society for Neuro-Oncology Annual Meeting Mumbai, India Invited Lecture 2013 Management of Glioblastoma in the Elderly Current Trends in the Management of Malignant Gliomas Rio de Janeiro, Brazil Invited Lecture 2013 Antiangiogenic therapy for glioblastoma 3rd Annual REDLANO meeting Cartagena, Colombia Invited Lecture 2013 Antiangiogenic agents for therapy of gliomas Central Nervous System Malignancies Symposium Vienna, Austria Invited Lecture 2013 Glioblastoma at recurrence V International Conference on Future Trends in the Treatment of Brain Tumors Bologna, Italy Invited Lecture 2014 Primary CNS Lymphoma Asian Society for Neuro-Oncology Annual Meeting Istanbul, Turkey Invited Lecture Tracy T. Batchelor 4/29/201729 Report of clinical activities and innovations Current Licensure and Certification: 1991 Diplomate National Board of Medical Examiners 1995-2005 Diplomate American Board of Psychiatry and Neurology (Neurology) 2005-2015 Diplomate Recertification American Board of Psychiatry and Neurology (Neurology) 2011-2021 Certified United Council of Neurologic Subspecialties (NeuroOncology) 1994-1998 Medicine State of New York 1995-1996 Medicine State of New Jersey 1995-present Medicine Commonwealth of Massachusetts Practice Activities: Ambulatory Neuro-Oncology Practice Tuesdays, Wednesdays, 3 sessions weekly Massachusetts General Hospital, Yawkey 9E, Boston Ambulatory Neuro-Oncology Practice Massachusetts General Hospital West, Waltham Alternating Friday mornings, 1 session monthly Inpatient Neuro-Oncology Attending 6 weeks per year Clinical Innovations: My clinical research has influenced the therapy of patients with newly diagnosed and relapsed primary CNS lymphoma emphasizing the use of high-dose intravenous methotrexate in both of these settings. My clinical research may also impact the therapy of glioblastoma as we have taken a novel oral agent from early phase clinical trials to an international randomized trial. Educational Material for Patients and the Lay Community Activities 2009 Invited lecture for lay public/brain tumor patients Florida Brain Tumor Association 2005-present Best Doctors in America (Neurology) Best Doctors in America® 2011-present Best Doctors in Boston (Neurology) Boston Magazine 2011-present Top Doctors in the United States (Neurology) U.S. News and World Report 2011-present Top Doctors (Top 1% of Specialty, Neurology) Castle and Connolly Recognition Tracy T. Batchelor 4/29/201730 Report of Scholarship Peer-reviewed publications Research Investigations 1. Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology 1997; 48: 1234-1238. 2. Batchelor TT, Kroll GS, DeAngelis LM. Neuroimaging abnormalities in patients with hypoglossal nerve palsies. J Neuroimaging 1997; 7: 86-88. 3. Batchelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998; 40: 131-136. 4. Dalmau J, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR. Ma1, a novel neuron- and testis-specific protein is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 1999; 122: 27-39 5. Glantz MJ, LaFollete S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D, Cowens W, Howell SB. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110-3116 6. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84: 157-163 7. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Lancet Oncol 2001; 2: 354-365 8. Batchelor TT, Leahy N, Kaufman D. Methotrexate chemotherapy for isolated central nervous system relapse of testicular lymphoma. Clin Lymphoma 2001; 2: 116-119 9. Jaeckle KA, Batchelor TT, O’Day SJ, et al. An open label trial of sustained release cytarabine (Depocyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002; 57: 231-239 10. Batchelor TT, Kolak G, Ciordia R, Foster CS, Henson JW. Methotrexate for intra-ocular lymphoma. Clin Cancer Res 2003; 9: 711-715 11. Batchelor TT, Carson K, O’Neill A, Alavi J, New P, Grossman SA, Hochberg F, Priet R for the NABTT CNS Consortium. The treatment of primary central nervous system lymphoma (PCNSL) with methotrexate and deferred radiotherapy: NABTT 96-07. J Clin Oncol 2003; 21: 1044-1049 12. Braaten KM, Betensky R, Okada Y, de Leval L, Hochberg F, Louis DN, Harris NL, Batchelor TT. Bcl-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063-1069 13. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumors: the clinical spectrum and outcome of treatment. Neurology 2003; 61: 696-698 14. Fine HA, Wen PY, Maher EK, Viscosi E, Batchelor T, Figg WD, Purow BJ, Borkowf C. A phase II trial o f thalidomide and BCNU for patients with recurrent high grade gliomas. J Clin Oncol 2003; 21: 2299-2304 15. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub RT, Louis DN. Accurate prediction of high grade glioma outcome by gene expression profiling. Cancer Res 2003; 63: 1602-1607 Tracy T. Batchelor 4/29/201731 16. Gilbert MR, Supko JG, Batchelor TT, Lesser G, Priet R, Piantadosi S, Grossman SA. Phase I clinical trial and pharmacokinetic study of Irinotecan in adult patients with recurrent malignant glioma. Clin Cancer Res 2003; 9: 2940-2949 17. Batchelor TT, Gilbert MR, Supko JG, Carson K, O’Neill AM, Grossman SA, Lesser G, Mikkelsen T, Phuphanich S, Alavi J, New P for the NABTT CNS Consortium. A phase II study of CPT-11 in adults with recurrent malignant glioma: final report of NABTT 97-119. Neuro-Oncol 2004; 6: 21-27 18. Batchelor TT, Betensky RA, Esposito JM, Pham L, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10: 228-233 19. He X, Batchelor TT, Grossman SA, Supko, JG. Determination of procarbazine in human plasma by high performance liquid chromatography with electrospray ionization mass spectrometry. J Chromat B Analyt Technol Biomed Life Sci 2004; 799: 281-291 20. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Batchelor TT. Treatment of central nervous system lymphoma with sequential courses of high-dose methotrexate. Clin Cancer Res 2004; 10: 5643-5646 21. Betensky RA, Nutt CL, Batchelor TT, Louis DN. Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancers. J Mol Diagn 2005; 7: 276-282 22. Nguyen PL, Chakravarti A, Finkelstein DM, Hochberg FH, Batchelor TT, Loeffler JS. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol 2005; 23: 1507-1513 23. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histological subtypes of high-grade gliomas. Clin Cancer Res 2005; 11: 22582264 24. Shenkier TN, Blay J-Y, O’Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJM, Ponzoni M, O’Brien P, Rubenstein J, Connors JM. Primary CNS lymphoma of T cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23: 2233-2239 25. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 2005; 63: 704-710 26. Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O’Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F. Report of an international workshop to standardize baseline evaluation and response criteria for primary central nervous system lymphoma. J Clin Oncol 2005; 23: 5034-5043 27. Aghi M, Gaviani P, Henson J, Batchelor TT, Louis DN, Barker FG. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 2005; 11: 86008605 28. Rubenstein JL, Shen A, Fridlyand J, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Hyun W, Parikh S, Jain A, Haqq C, Shuman M. Gene expression, angiotropism and outcome in primary CNS lymphoma. Blood 2006; 3716-3723 29. Shah GD, Kesari S, Xu R, Batchelor TT, O’Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-Oncol 2006; 8: 38-46 Tracy T. Batchelor 4/29/201732 30. Jahnke K, Korfel A, O’Neill BP, Blay J-Y, Abrey LE, Martus P, Poortmans PMP, Shenkier TN, Batchelor TT, Neuwelt EA, Raizer J, Schiff D, Pels H, Herrlinger U, Stein H, Thiel E. International primary central nervous system lymphoma collaborative group (IPCG) study on low-grade primary central nervous system lymphoma in immunocompetent patients. Ann Neurol 2006; 59: 755-762 31. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O’Meara S, Parker A, Avis T, Barthope S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006; 66: 3987-3993 32. Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res 2006; 12: 5174-5181 33. Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade and survival. J Neuropathol Exp Neurol 2006; 65: 1181-1188 34. Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 2007; 59: 817-823 35. Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M, Ancukiewicz M, Mrugala M, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF and PDGF receptor tyrosine kinase inhibitor normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95 36. Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JEC, Abrey LE, Batchelor TT, Schiff D. Cognitive functions in primary CNS lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18: 1145-1151 37. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry ST, Iafrate AJ, Louis DN. Loss of mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007, 13: 2038-2045. 38. Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O’Neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncol 2007; 9: 354-363 39. Eichler AF, Batchelor TT, Henson JW. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-oncol 2007; 9: 373-377 40. Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay J-Y, Ferreri AJM, Omuro AMP, Thiel E, Abrey LE. Primary intraocular lymphoma: An international primary central nervous system lymphoma collaborative group report. Ann Oncol 2007; 18: 1851-1855 41. Kesari S, Schiff D, Henson JW, Muzikansky A, Doherty L, Gigas DC, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black P, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide and celecoxib for newly-diagnosed glioblastoma in adults. Neuro-oncol 2008; 10: 300-308 Tracy T. Batchelor 4/29/201733 42. Voloschin AD, Betensky R, Wen PY, Hochberg FH, Batchelor TT. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86: 211-215 43. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome of primary CNS lymphoma patients treated with high-dose methotrexate and deferred radiation. Neurology 2008; 70: 401-402 44. Grossman SA, Olson J, Batchelor TT, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro-oncol 2008; 10: 190-198 45. Sorensen AG, Batchelor TT, Zhang W-T, Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008; 5: 634-647 46. Doolittle ND, Abrey LE, Shenkier TN, Siegal T, Bromberg JEC, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system (CNS) relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Collaborative Group report. Blood 2008; 111: 1085-1093 47. Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2008; 88: 43-50 48. Gerstner ER, Abrey LE, Schiff D, Ferreri AJM, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL, Batchelor TT. CNS Hodgkin lymphoma. Blood 2008; 112: 1658-1661 49. Grossman SA, Carson K, Phuphanich S, Batchelor T, Peereboom D, Nabors LB, Lesser G, Hausheer F, Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-oncol 2008; 10: 608-616 50. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J, Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto FM, Abrey LE. Primary CNS lymphoma with intraocular involvement: International PCNSL collaborative group report. Neurology 2008; 71: 1355-1360 51. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor T, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009; 73: 222-227 52. Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT. High dose methotrexate for elderly patients with primary central nervous system lymphoma. Neuro-oncol 2009; 11: 211-215 53. Rubenstein J, Shen A, Batchelor T, Kadoch C, Treseler P, Shuman M. Differential gene expression in CNS lymphoma. Blood 2009 (in press) 54. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK. Edema control by cediranib, a VEGF targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27: 2542-2552 55. Gerstner ER, Duda DG, di Tomaso E, Ryg PA, Loeffler JS, Sorensen AG, Ivy P, Jain RK, Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Clin Pract Oncol 2009; 6: 229236 Tracy T. Batchelor 4/29/201734 56. Grossman S, Ye X, Chamberlain M, Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J, Fine H. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol 2009; 27: 4155-4161 57. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A vascular normalization index as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009; 69: 5296-5300 58. Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen AG. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro-oncol 2010; 12: 466-472 59. Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with new diagnosed glioblastoma. Neurology 2009; 73: 1509-1510 60. Michaud DS, Holick CN, Batchelor T, Giovanucci E, Hunter DJ. Prospective study of meat intake, dietary nitrates, nitrites and nitrosamines and risk of adult glioma. Am J Clin Nutr 2009; 90: 1-8 61. Aghi MK, Batchelor TT, Louis DN, Barker FG 2nd, Curry WT Jr. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol 2009; 93: 115-120 62. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro-oncol 2010; 12: 603-607 63. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78: 85-90 64. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 2010; 100: 261-268 65. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D. Siegal, T. Neurolymphomatosis: an international primary central nervous system collaborative group report. Blood 2010; 115: 5005-5011 66. Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-2823 67. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neurooncol 2010; 12: 1071-1077 68. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010; 31: 1135-1143 69. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle C, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Neurooncol2011; 103: 325-332 Tracy T. Batchelor 4/29/201735 70. Kahn J, Loeffler J, Niemierko A, Chiocca A, Batchelor T, Chakravarti A. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys2010 (Epub, October 13) 71. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary central nervous system lymphoma. Neurology 2011; 76: 929-930 72. Abla O, Weitzman S, Blay J-Y, O’Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Silver M, Betensky R, Batchelor TT. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG) Clin Cancer Res 2011; 17: 346-352 73. di Tomaso E, Snuderl M, Kamoun W, Duda D, Auluck P, Frosch M, Wen P, Plotkin S, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of “rebound” revascularization and change in growth pattern as mode of escape. Cancer Res 2011; 71: 19-28 74. Mohapatra G, Engler DA, Starbuck KD, Kim JC, Bernay DC, Scangas GA, Batchelor TT, Betensky RA, Louis DN. Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genome hybridization. Acta Neuropath 2011; 121: 529-543 75. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011; 6: e17948 76. Kim H, Catana C, Ratai EM, Andronesi OC, Jennings D, Batchelor TT, Jain RK, Sorensen AG. Serial MRI spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res 2011; 71: 3745-3752 77. Emblem KE, Bjornerud A, Mouridsen K, Borra RJ, Batchelor TT, Jain RK, Sorensen AG. T(1)- and T(2)(*)dominant extravasation correction in DSC-MRI: Part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients. J Cereb Blood Flow Metab 2011; 31: 2054-2064 78. Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, Lacasce AS, Fisher DC, Abramson JS, Armand P, Chen YB. Autologous stem cell transplantation with thiotepa, busulfan and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2012; 18: 76-83 79. Patrij K, Reiser M, Watzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, VogtSchaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG. Isolated central nervous system relapse of systemic lymphoma (SCNCL): clinical features and outcome of a retrospective analysis. Ger Med Sci 2011 Epub 2011 80. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol 2011; 29: 3211-3213 81. Chan C-C, Rubenstein J, Coupland S, Davis J, Harbour JW, Johnston P, Cassoux N, Touitou V, Smith J, Batchelor T, Pulido J. Primary vitreoretinal lymphomas: a report from the international primary central nervous system lymphoma collaborative group symposium. Oncologist2011; 16: 1589-1599 82. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 2011; 13: 1324-1330 83. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass S, Raizer JJ, Wen PY. Phase I study of Tracy T. Batchelor 4/29/201736 panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol 2012; 107: 133138 84. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to anti-angiogenic therapy with elevated blood perfusion. Cancer Res 2012; 72: 402-407 85. Goldlust SA, Cavaliere R, Newton HB, Hsu M, DeAngelis LM, Batchelor TT, Gilbert MR, Lassman AB. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors. J Neurooncol 2012; 107: 407-411 86. Andronesi OC, Kim G, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Trans Med 2012; 4: 116 87. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA for the New Approaches to Brain Tumor Therapy (NABTT) Central Nervous System Consortium. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer 2012; 118: 5601-5607 88. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 2012; 30: 3258-3263 89. Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellison L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 2012; 110: 89-98 90. Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger D, Ellisen L, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a distinct subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013; 31: e233-236 91. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013; 121: 745-751 92. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013; 15: 930-935 93. Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJH, Wen PY, Batchelor TT, Rosen B, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 2013; 19: 1178-1183 94. Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages (TAMs) after antiangiogenic therapy is associated with poor survival in recurrent glioblastoma patients. Neurooncol 2013; 15: 1079-1087 95. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby L, de Groot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jurgensmeier J, Jain R, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31: 3212-3218 Tracy T. Batchelor 4/29/201737 96. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013; 123: 3659-3663 97. Taylor JW, Flanagan EP, O’Neill BP, Siegal T, Omuro AMP, DeAngelis LM, Baehring JM Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor TT, Blay J-Y, Korfel A, Betensky RA, Lopes M-B, Schiff D. Primary leptomeningeal lymphoma: an international primary CNS lymphoma collaborative group report. Neurology 2013; 81: 1690-1696 98. Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression in newly diagnosed glioblastoma patients treated with a VEGF inhibitor in combination with chemoradiation. Oncologist 2014; 19: 75-81 99. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy P, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib and chemoradiation. Proc Natl Acad Sci 2013; 110: 19059-19064 100. Reuter M, Gerstner ER, Rapalino O, Batchelor TT, Rosen B, Fischl B. Impact of MRI head placement on glioma response assessment. J Neurooncol 2014 (Epub ahead of print) 101. Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, DiasSantagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden M, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 2014 (Epub ahead of print) 102. Poynton CB, Chen KT, Chonde DB, Izquierdo-Garcia D, Gollub RL, Gerstner ER, Batchelor TT, Catana C. Probabilistic atlas-based segmentation of combined T1-weighted and DUTE MRI for calculation of head attenuation maps in integrated PET/MRI scanners. Am J Nucl Med Mol Imaging 2014; 4: 160-171 103. Chen Y-B, Batchelor TT, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi A, Dietrich J, Driscoll J, Gerstner E, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Phase 2 trial of high-dose rituximab with cytarabine mobilization therapy and thiotepa, busulfan, and cyclophosphamide (R-TBC) autologous stem cell transplant in patients with CNS involvement by non-Hodgkin lymphoma. Cancer (in press) Case Reports 1. Batchelor TT, Platten M, Palmer-Toy DE, Hunter GJ, Lev MH, Dalmau J, Hochberg FH. Chorea as a paraneoplastic complication of Hodgkin’s disease. J Neurooncol 1998; 36: 185-190. 2. Multani P, Supko J, Batchelor T, Goodman AK, Seiden M. Case report: Effective treatment of leptomeningeal metastasis from ovarian cancer with topotecan. Cancer Therapeutics 1998; 1: 33-36. 3. Henson JW, Yang J, Batchelor T. Letter: Vitreous methotrexate concentration after high-dose intravenous therapy for primary central nervous system lymphoma. J Clin Oncol 1999; 17: 1329 4. Quinones-Hinojosa A, Friedlander RM, Boyer PJ, Batchelor TT, Chiocca EA. Solitary sciatic nerve lymphoma followed by neurolymphomatosis: case report and review. J Neurosurg 2000; 92: 165-169 5. Ferreri AJM, Batchelor T, Zucca E, Armitage J, Cavalli F. An international collaborative group against primary central nervous system lymphoma. J Clin Oncol 2003; 21: 1649-1650 6. Voloschin AD, Louis DN, Cosgrove GR, Batchelor TT. Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q- deleted anaplastic oligoastrocytoma: case study. Neuro-Oncol 2005; 7: 97-101 Tracy T. Batchelor 4/29/201738 7. Gaviani P, Gonzalez RG, Zhu JJ, Batchelor TT, Henson JW. Central neurogenic hyperventilation and lactate production in brainstem glioma. Neurology 2005; 64: 166-167 8. Gerstner ER, Frosch MP, Batchelor TT. Diffusion MRI detects pathologically confirmed, non-enhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010; 28: 91-93 9. Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Bevacizumab exacerbating cerebral radiation necrosis. J Clin Oncol 2010; 29: e159-162 10. Chi AS, Batchelor TT, Kwak E, Clark J, Wang DL, Wilner KD, Louis DN, Iafrate AJ. Rapid radiographic and clinical improvement after treatment of a MET-amplified, recurrent glioblastoma with a MET inhibitor (crizotinib). J Clin Oncol 2012; 30: e30-33 11. Clark SW, Taylor J, Wang DL, Abramson JS, Batchelor TT. Plasmablastic lymphoma after standard dose temozolomide for newly diagnosed glioblastoma. Neurology 2013; 81: 93-94 Other publications Reviews, chapters, monographs, editorials 1. Batchelor TT, DeAngelis LM. Medical management of cerebral metastases. In: Harsh GR, ed. Management of cerebral metastases. Neurosurg Clin N Am Philadelphia: WB Saunders; 1996; 7: 435-446 2. Batchelor TT, Louis DN. Case records of the Massachusetts General Hospital, A 67-year-old-woman with the cauda equina syndrome. N Engl J Med 1997; 337: 1829-1837. 3. Batchelor TT. Neuro-oncologic diseases. In: Cudkowicz ME, Irizarry MC, eds. Neurologic disorders in women. Boston: Butterworth-Heinemann; 1997. p. 57-83. 4. Schiff D, Batchelor TT, Wen PY. Neurologic emergencies in cancer patients. In: Feske SK, Wen PY, eds. Neurologic emergencies. Neurol Clin Philadelphia: WB Saunders; 1998; 16: 449-483 5. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist 1999; 4: 209224 6. Jeyapalan SA, Batchelor TT. Diagnostic evaluation of neurologic metastases. Cancer Invest 2000; 18: 381394 7. Piscatelli N, Batchelor TT. Epidemiology of brain tumors. UpToDate in Oncology. Wellesley: UpToDate, Inc. 2000 8. Batchelor TT, Hochberg FH. Primary central nervous system lymphoma. UpToDate in Oncology. Wellesley: UpToDate, Inc. 2000 9. Ciordia R, Supko J, Gatineau M, Batchelor TT. Cytotoxic chemotherapy: advances in delivery, pharmacology and testing. Curr Oncol Rep 2000; 2: 445-453 10. Batchelor TT. Commentary: Temozolomide for Malignant Gliomas. Lancet 2000; 355: 1115-1116 11. Batchelor TT, Cook SF. Clinimetric methods. In: Batchelor TT, Cudkowicz ME, eds. Neuroepidemiology. Boston: Butterworth-Heinemann 2001 Principles of 12. Batchelor TT, Piscatelli N, Alderson L. Brain tumors. In: Batchelor TT, Cudkowicz ME, eds. Principles of Neuroepidemiology. Boston: Butterworth-Heinemann 2001 Tracy T. Batchelor 4/29/201739 13. Plotkin SR, Batchelor TT. Advances in therapy for primary central nervous system lymphoma. Clin Lymphoma 2001; 1: 263-275 14. Batchelor TT, Gattineau MP, Supko JG. Pharmacological considerations on delivering chemotherapeutic agents to brain tumors. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott-Raven 2001; 657-677 15. Batchelor TT, Louis DN. Pathology and biology of high grade astrocytomas. Wellesley: UpToDate, Inc. 2001 UpToDate in Oncology. 16. Batchelor TT. Clinical manifestations and diagnosis of high grade astrocytomas. UpToDate in Oncology. Wellesley: UpToDate, Inc. 2001 17. Batchelor TT. Management of high grade astrocytomas. UpToDate in Oncology. Wellesley: UpToDate, Inc. 2001 18. Batchelor TT and Supko JG. Experimental treatments for high grade astrocytomas. UpToDate in Oncology. Wellesley: UpToDate, Inc. 2001 19. Batchelor TT, Stanley K, Andersen J. Clinical Trials in Neuro-Oncology. Curr Opin Neurol 2001; 14: 689694 20. Kesari S, Batchelor TT. Leptomeningeal metastases. In: Wen PY (ed) Neurologic Complications of Cancer, Neurol Clin 2002; 21: 1-42 21. Plotkin SR, Batchelor TT. Primary nervous system lymphoma. Curr Treat Options Oncol 2002; 3: 525-535 22. Lawler B, Batchelor TT. Primary and metastatic brain tumors. In: Skeel RT (ed), Handbook of Cancer Chemotherapy, 5th edition. Philadelphia: Lippincott Williams and Wilkins 2003; 378-388 23. Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage JO, Batchelor TT. Management of primary central nervous system lymphoma – a summary statement from the 8th International Conference on Malignant Lymphoma. J Clin Oncol 2003; 21: 2407-2414 24. Upchurch K, Batchelor TT. Clinical Features of Primary Central Nervous System Lymphoma. In: Batchelor TT. Lymphoma of the Nervous System. Boston: Butterworth-Heinemann, 2004 25. Henson JW, Batchelor TT. Intraocular Lymphoma. In: Batchelor TT. Lymphoma of the Nervous System. Boston: Butterworth-Heinemann, 2004 26. Drappatz J, Batchelor TT. Neurological complications of plasma cell disorders. In: Batchelor TT. Lymphoma of the Nervous System. Boston: Butterworth-Heinemann, 2004 27. Batchelor TT, Dorfman MV, Hunter DJ. The epidemiology of primary brain tumors. In: Black PM, Loeffler JS (eds). Cancer of the Nervous System. Philadelphia: Lippincott Williams and Wilkins, 2004 28. Batchelor TT, Dorfman MV, Hunter DJ. Epidemiology. In: Bradley WB, Daroff RB, Fenichel GM, Jankovic J. Neurology in Clinical Practice. Boston: Butterworth-Heinemann, 2004 29. Voloschin A, Batchelor TT, Allen JC. Management of primary nervous system tumors in infants and children. In: Bradley WB, Daroff RB, Fenichel GM, Jankovic J. Neurology in Clinical Practice. Boston: ButterworthHeinemann, 2004 30. Drappatz J, Batchelor TT. Neurological complications of plasma cell disorders. Clin Lymphoma 2004; 5: 163171 Tracy T. Batchelor 4/29/201740 31. Jeyapalan SA, Batchelor TT. Brain Metastases. Curr Treat Options Neurol 2004; 6: 273-284 32. Ferreri AJM, Batchelor T, Cavalli F. World experts join forces against primary CNS lymphomas. Cancer Futures 2004; 3: 113-116 33. DeAngelis L, Batchelor T. Primary CNS Lymphoma: Is there a role for prophylaxis against lymphomatous meningitis? Expert Rev Neurother 2004; 4: S19-S24 34. Grier JT, Batchelor TT. Metastatic neurological complications of non-Hodgkin’s lymphoma. Curr Oncol Rep 2005; 7: 55-60 35. Batchelor TT, Buchbinder BD, Harris NL. Case records of the Massachusetts General Hospital, A 32 year old woman with difficulty walking, headache and nausea. N Engl J Med 2005; 352: 185-194 36. Drappatz J, Batchelor TT. Leptomeningeal and Peripheral Nerve Metastases. In: Schiff D (ed). NeuroOncology Continuum 2005; 11: 47-68 37. Fitzsimmons AL, Upchurch KU, Batchelor TT. Clinical features and diagnosis of primary central nervous system lymphoma. In: Abrey LE, DeAngelis LM (eds). Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am 2005; 19: 689-703 38. Mrugala MM, Batchelor TT, Plotkin SR. Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 2005; 18: 604-610 39. Mrugala MM, Batchelor TT, Supko JG. Delivering anticancer drugs to brain tumors. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy, 4th edition. Philadelphia: Lippincott-Raven 2005: 484-501 40. Batchelor TT. Primary Central Nervous System Lymphoma. In: Vose JM (ed). Lymphoma Annual Update 2005. Clinical Care Options 2005 41. Batchelor TT. Neuro-oncology update: 2005. Curr Opin Neurol 2005; 18: 631 42. Batchelor TT, Loeffler JS. Primary central nervous system lymphoma. J Clin Oncol 2006; 24: 1281-1288 43. Grier JT, Batchelor TT. Low-grade gliomas. Oncologist 2006; 11: 681-693 44. Mrugala MM, Newcomer A, Batchelor TT. Primary central nervous system lymphoma. In: Gilman S (ed), Neurobiology of Disease New York: Academic Press, 2006; 395-412 45. Eichler AF, Batchelor TT. Primary central nervous system lymphoma: clinical presentation and diagnosis. Neurosurg Focus 2006; 21: E15 46. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006; 20: 1337-1361 47. Voloschin AD, Batchelor TT. Paraneoplastic syndromes. In: Brust JCM (ed). Current Diagnosis and Treatment - Neurology. New York: McGraw Hill 2007; 165-174 48. Eichler AF, Batchelor TT. Chapter 16: Primary and metastatic brain tumors. In: Skeel RT (ed), Handbook of Cancer Chemotherapy, 7th edition. Philadelphia: Lippincott Williams and Wilkins 2007 49. Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Expert Rev Anticancer Ther 2007; 7: 689-700 50. Batchelor TT, Loeffler JS. Update on primary CNS lymphoma. Am Soc Clin Oncol Ed Book, 442-448, 2007 Tracy T. Batchelor 4/29/201741 51. Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie 2007; 30: 90-91 52. Gerstner ER, Batchelor TT. Angiogenesis-targeting therapeutics for glioblastoma. Investigational Drugs 2007; 16: 1895-1908 Expert Opinion 53. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13: 223-230 54. Drappatz J, Batchelor TT. Leptomeningeal Metastases. Curr Treat Options Neurol 2007; 9: 283-293 55. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci 2007; 8: 610-622 56. Batchelor TT, Byrne TN. Neurological complications of primary brain tumors. In: Schiff D, Kesari S, Wen PY. Cancer Neurology in Clinical Practice, Humana Press: Totowa, 2008, 381-396 57. Batchelor TT, Ferreri A. Primary CNS lymphoma. In: Cavalli F, Stein H, Zucca E (Eds). Extranodal Lymphomas, Informa Healthcare: London, 2008, 127-138 58. Chi A, Batchelor TT. Chapter 63: Primary brain tumors. In: Chabner BA, Lynch TJ, Longo DL (Eds). Harrison’s Manual of Oncology. New York: McGraw Hill, 2008; 567-575 59. Jain RK, Duda DG, Batchelor TT, Sorensen AG, Willett CG. Normalization of tumor vasculature and microenvironment as a potential mechanism of action of antiangiogenic therapies: Clinical evidence and implications. In: Folkman J (Ed). Angiogenesis, 2008 60. Jain RK, Batchelor TT, Duda DG, Willett CG. Normalization of tumor vasculature and microenvironment as a potential mechanism of action of antiangiogenic therapies. In Teicher BA, Ellis LH (Eds) Anti-Angiogenic Agents in Cancer Therapy, 2nd Ed. New York: Humana Press, 2008 61. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008; 8: 541-553 62. Gerstner ER, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability and angiogenesis in gliomas. Curr Opin Neurol 2008; 6: 728-735 63. Gerstner ER, Batchelor TT. Leptomeningeal metastases. In: Rosenfeld M, Dalmau J (Eds). Neuro-Oncology Section, In: Lisak R, Truong DD, Carroll W, Bhidayasiri R (Eds). International Neurology: A Clinical Approach. Boston: Blackwell International, 2009 64. Gerstner ER, Batchelor TT. CNS lymphomas. In: Vose JM (Ed). Lymphomas (in press) 65. Gerstner ER, Batchelor TT. Primary CNS Lymphoma. In: Winn R (ed) Youmans Neurological Surgery, 6 th Edition. New York: Elsevier (in press) 66. Mrugala MM, Ponzoni M, Rubenstein J, Batchelor TT. Biology of diffuse large B-cell lymphoma in the central nervous system. Curr Oncol Rep 2009; 11: 73-80 67. Chi A, Batchelor TT. Angiogenesis-targeting therapies for glioblastoma. Oncologist 2009; 14: 621-636 68. Gerstner ER, Batchelor TT. VEGF-targeting therapies for glioblastoma. In: Van Meir EG (ed) CNS Cancer: models, prognostic factors and targets. New York: Humana Press 2009 69. Dietrich J, Wang DL, Batchelor TT. Cediranib, a novel pan-VEGF receptor tyrosine kinase inhibitor, for the treatment of glioblastoma. Expert Opin Inv Drug 2009; 18: 1549-1557 Tracy T. Batchelor 4/29/201742 70. Cahill DP, Codd PJ, Batchelor TT, Curry WT, Louis DN. MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. Clin Neurosurg 2008; 55: 165-171 71. Gerstner ER, Batchelor TT. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep 2009; 9: 254-262 72. Drappatz J, Batchelor TT. Leptomeningeal Metastases. Am Soc Clin Oncol Ed Book 2009 73. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338 74. Brastianos PK, Batchelor TT. VEGF inhibitors in brain tumors. Clin Adv Hematol Oncol 2009; 7: 753-760 75. Gerstner ER, Batchelor TT. CNS lymphomas. Arch Neurol 2010; 67: 291-297 76. Chen CC, Hochberg F, Batchelor T, Shih HA, Chakravarti A, Chapman, Loeffler J. Radiogsurgery as salvage therapy for primary central nervous system lymphoma. In: McDermott MW (ed) Radiosurgery. Basel, Karger 2010, vol 7, 276-287 77. Quant E, Wang DL, Batchelor TT. EGFR-targeting therapies for malignant gliomas. Curr Cancer Ther Rev 2011; 7: 65-77 78. Batchelor TT, Grigg A, Thiel E. Chemotherapy. In: Batchelor TT, Deangelis LM (eds) Lymphoma and Leukemia of the Nervous System, 2d Edition. New York, Springer 2012 79. Batchelor TT, Wang D, Neuwelt E, Gonzalez RG. Diagnostic Considerations. In: Batchelor TT, Deangelis LM (eds) Lymphoma and Leukemia of the Nervous System, 2d Edition. New York, Springer 2012 80. Gerstner ER, Batchelor TT. CNS Lymphoma. In: Norden A, Reardon D, Wen PY (eds). Primary Brain Tumors: Pathogenesis and Therapy. New York: Humana Press (in press) 81. Eichler AF, Batchelor TT. Chapter 16: Primary and metastatic brain tumors. In: Skeel RT (ed), Handbook of Cancer Chemotherapy, 8th edition. Philadelphia: Lippincott Williams and Wilkins 2010 82. Merrell RT, Dietrich J, Batchelor TT. Anti-metabolites. In: Wen PY, Schiff D, Quant E (eds). Neurologic complications of cancer therapy. New York: Demos Medical Publishing 83. Brastianos PK, Batchelor TT. Angiogenesis and novel targeted agents in malignant gliomas. Targ Oncol 2010; 5: 167-174 84. Gerstner ER, Dietrich J, Batchelor TT. Role of cediranib in glioblastoma. Controversies in Neuro-Oncology (in press) 85. Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol 2010; 22: 598-603 86. Illerhaus G, Batchelor TT. CNS lymphoma: biomarker better than biopsy? Blood 2011; 117: 2987-2989 87. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for the treatment of glioblastoma. Neuro-Oncol 2011; 13: 566-579 88. Batchelor TT, Sorensen AG, Louis DN. A 54-year-old man with visual field loss and a mass in the brain. N Engl J Med 2012; 366: 2112-2120 89. Gerstner ER, Batchelor TT. Anti-angiogenic agents. Cancer J 2012; 18: 45-50 Tracy T. Batchelor 4/29/201743 90. Brastianos PK, Batchelor TT. Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Clin N Am 2012; 26: 897-916 91. Brastianos PK, Batchelor TT. Chapter 492: Primary central nervous system lymphoma. In: Aminoff MJ, Daroff RB (eds).Encyclopedia of the Neurological Sciences (in press). Oxford: Elsevier 92. Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J 2012; 18: 463-468 93. de Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma. Am Soc Clin Oncol Educ Book 2013; 2013: 71-78 94. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 2013; 10: 14-26 95. Nayak L, Batchelor TT. Recent advances in the treatment of primary central nervous system lymphoma. Curr Treat Options Oncol 2013 (Epub) 96. Ponzoni M, Issa A, Batchelor TT, Rubenstein JL. Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol 2014; 25: 316-322 97. Batchelor TT. Flying solo: chemotherapy without radiation for primary CNS lymphoma. J Clin Oncol 2013; 31: 3051-3053 98. Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low grade gliomas. Oncologist 2014; 19: 403-413 99. Batchelor TT. Comment: Defining cure in primary CNS lymphoma. Neurology 2014; 82: 1373 100. Batchelor TT. Primary CNS Lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA (eds). DeVita, Hellman and Rosenberg’s Cancer: Principles and practice of oncology, 9 th ed. Lippincott, Williams and Wilkins 101. Ferreri AJM, Zucca E, Armitage J, Cavalli F, Batchelor TT. Ten years of International PCNSL Collaborative Group studies. J Clin Oncol 2013; 31: 3444-3445 Books/Textbooks 1. Batchelor TT, Cudkowicz ME. Principles of Neuroepidemiology. Boston: Butterworth-Heinemann, 2001 2. Batchelor TT. Lymphoma of the Nervous System. Boston: Butterworth-Heinemann, 2004 3. Batchelor TT, DeAngelis LM (eds). Lymphoma and Leukemia of the Nervous System. 2nd Edition. New York: Springer, 2012 4. Batchelor TT (Section Editor, Cancer and the Nervous System). In: Bradley WB, Daroff RB, Fenichel GM, Jankovic J. Neurology in Clinical Practice. Boston: Butterworth-Heinemann, 2004, 2007, 2012 5. Batchelor TT (Section Editor, Neuro-Oncology). In: Chabner BA, Lynch TJ, Longo DL. Harrison’s Manual of Oncology, Columbus: McGraw-Hill, 2007, 2013 6. Batchelor TT, Nishikawa R, Tarbell NJ, Weller M. Oxford Textbook of Neuro-Oncology. Oxford: Oxford University Press (2015 publication date) Tracy T. Batchelor 4/29/201744 Narrative Report I am a neuro-oncologist with an established record as a translational investigator, clinician, teacher and administrator. My primary research interest is to identify and study novel therapeutic approaches in patients with high-grade gliomas and primary central nervous system lymphoma. Based on my publication record, peer-reviewed NIH grant funding, trainee record and clinical practice I have achieved both national and international reputations as a translational investigator. My work involves the development of novel therapeutics for malignant primary brain tumors. Our investigations in glioblastoma emphasize the development of imaging and tumor markers of sensitivity and resistance to antiangiogenic therapeutics in preclinical models and humans. We employ novel MRI and PET imaging techniques in order to define subpopulations of glioblastoma patients most likely to benefit from agents targeting vascular endothelial growth factor (VEGF). We are also involved in defining and exploiting alternative pro-angiogenic targets in order to augment and extend responses to anti-VEGF therapeutics. I am also involved in early phase human trials of targeted therapeutics in molecularly defined subsets of glioblastoma. I have played central roles in defining the optimal diagnostic and treatment pathways for primary CNS diffuse large B-cell lymphoma (PCNSL). I co-founded the International PCNSL Collaborative Group more than a decade ago and I remain the chair of this organization of over 125 hematologists, neurologists and oncologists from more than 20 countries. In the setting of local, national and international studies we have established the currently recommended diagnostic evaluation for newly diagnosed PCNSL patients. I have also spearheaded key chemotherapy trials for PCNSL contributing to currently recommended treatment guidelines for PCNSL. Tracy T. Batchelor 4/29/201745
